The strong efficacy and safety data could drive near-term stock appreciation. Monitor for updates on the U.S. IMPACT trial enrollment and any regulatory interactions. Given the company's small market cap and early-stage pipeline, this is a high-risk/high-reward catalyst.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $1.02entry
- T+1 · 7mo ago 0.00%α −0.80% · $1.02
- T+5 · 6mo ago 0.00%α −2.94% · $1.02
- T+20 · 6mo ago 0.00%α −5.65% · $1.02
- T+60 · 4mo ago +124.51%α +122.65% · $2.29
Price Chart
How similar events traded
Executive Summary
Alpha Tau announced positive clinical trial results for its Alpha DaRT therapy in pancreatic cancer, achieving 100% local disease control in 19 evaluable patients with a favorable safety profile. These results were presented at DDW 2026 and support the ongoing U.S. multicenter IMPACT trial, representing a significant milestone for the pre-commercialization biotech.
Key Facts
- 100% local disease control rate in evaluable patients from pooled analysis of two first-in-human trials of Alpha DaRT in pancreatic adenocarcinoma
- 15 of 19 evaluable patients (79%) achieved stable disease and 4 (21%) had partial response per modified RECIST v1.1
- Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
- Results presented at Digestive Disease Week (DDW) 2026, first oral presentation at a major gastroenterology conference
- Data supports ongoing U.S. multicenter pancreatic cancer IMPACT trial
Financial Impact
No financial figures provided; clinical milestone for pre-revenue company with $117M market cap
Risk Factors
- Early-stage clinical data with small sample size (n=19 evaluable) may not predict larger trial outcomes
- Alpha DaRT is not yet approved for commercial use in the U.S. or elsewhere
- Company has limited operating history and has incurred significant losses; may require additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051176 |
| Document: ea0288785-6k_alphatau.htm | 0001213900-26-051176 |
| Document: 0001213900-26-051176-index-headers.html | 0001213900-26-051176 |
| Document: 0001213900-26-051176-index.html | 0001213900-26-051176 |
| Document: 0001213900-26-051176.txt | 0001213900-26-051176 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers